| Currently at RMH |
|
|
|
|
|
|
|
|
|
|
|
| n | When NovoSeven
is requested / recommended |
|||||||||
| n | Direct
consultation with haematology consultant and |
|||||||||
| treating
consultant with patient |
||||||||||
| n | Usually only
considered after failure of aggressive non-red |
|||||||||
| cell blood
product support to achieve haemostasis |
||||||||||
| n | MPH: treating
consultant advised to contact health fund/ |
|||||||||
| hospital
management to get agreement for payment |
||||||||||
| n | Funding issues/
process: to be resolved |
|||||||||
| n | Increasing
frequency of requests |
|||||||||